JP6694808B2 - 抗腫瘍活性を有する新規な二重特異的結合分子 - Google Patents

抗腫瘍活性を有する新規な二重特異的結合分子 Download PDF

Info

Publication number
JP6694808B2
JP6694808B2 JP2016508054A JP2016508054A JP6694808B2 JP 6694808 B2 JP6694808 B2 JP 6694808B2 JP 2016508054 A JP2016508054 A JP 2016508054A JP 2016508054 A JP2016508054 A JP 2016508054A JP 6694808 B2 JP6694808 B2 JP 6694808B2
Authority
JP
Japan
Prior art keywords
seq
antibody
polypeptides
cells
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016508054A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516789A (ja
JP2016516789A5 (https=
Inventor
ブラー ファビアン
ブラー ファビアン
ビュルナー ウルリッヒ
ビュルナー ウルリッヒ
クルプシュ クリスティーナ
クルプシュ クリスティーナ
ツビンデン イレーネ
ツビンデン イレーネ
サンティマリア ロジャー
サンティマリア ロジャー
アッティンガー−トラー イザベッラ
アッティンガー−トラー イザベッラ
ケーニッヒ−フリードリヒ スーザン
ケーニッヒ−フリードリヒ スーザン
ベルトシンガー ジュリアン
ベルトシンガー ジュリアン
グラウブロウスキ ドラガン
グラウブロウスキ ドラガン
ブラック サイモン
ブラック サイモン
シラッチ ミケーラ
シラッチ ミケーラ
ウッズ リチャード
ウッズ リチャード
ヘシミ ヘレン
ヘシミ ヘレン
ヘンネ パトリシア
ヘンネ パトリシア
フォン デア ベイ ウルリーケ
フォン デア ベイ ウルリーケ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cilag GmbH International
Original Assignee
Covagen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covagen AG filed Critical Covagen AG
Publication of JP2016516789A publication Critical patent/JP2016516789A/ja
Publication of JP2016516789A5 publication Critical patent/JP2016516789A5/ja
Application granted granted Critical
Publication of JP6694808B2 publication Critical patent/JP6694808B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
JP2016508054A 2013-04-19 2014-03-06 抗腫瘍活性を有する新規な二重特異的結合分子 Expired - Fee Related JP6694808B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13164555.8 2013-04-19
EP13164555 2013-04-19
PCT/EP2014/054390 WO2014170063A1 (en) 2013-04-19 2014-03-06 Novel bispecific binding molecules with antitumoral activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019013831A Division JP2019106997A (ja) 2013-04-19 2019-01-30 抗腫瘍活性を有する新規な二重特異的結合分子

Publications (3)

Publication Number Publication Date
JP2016516789A JP2016516789A (ja) 2016-06-09
JP2016516789A5 JP2016516789A5 (https=) 2017-03-30
JP6694808B2 true JP6694808B2 (ja) 2020-05-20

Family

ID=48128216

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016508054A Expired - Fee Related JP6694808B2 (ja) 2013-04-19 2014-03-06 抗腫瘍活性を有する新規な二重特異的結合分子
JP2019013831A Pending JP2019106997A (ja) 2013-04-19 2019-01-30 抗腫瘍活性を有する新規な二重特異的結合分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019013831A Pending JP2019106997A (ja) 2013-04-19 2019-01-30 抗腫瘍活性を有する新規な二重特異的結合分子

Country Status (15)

Country Link
EP (1) EP2986630B1 (https=)
JP (2) JP6694808B2 (https=)
KR (1) KR20160002882A (https=)
CN (1) CN105189544A (https=)
AU (1) AU2014256037B2 (https=)
BR (1) BR112015026143A2 (https=)
CA (1) CA2908988A1 (https=)
CL (1) CL2015003085A1 (https=)
EA (1) EA201592006A1 (https=)
HK (1) HK1214605A1 (https=)
MX (1) MX2015014608A (https=)
PH (1) PH12015502278A1 (https=)
SG (1) SG11201508231UA (https=)
WO (1) WO2014170063A1 (https=)
ZA (1) ZA201507752B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
UA129760C2 (uk) 2013-12-17 2025-07-30 Дженентек, Інк. Анти-cd3 антитіло та спосіб його застосування
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
EP3916018A1 (en) 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
FI126633B (en) 2015-07-10 2017-03-15 Next Biomed Therapies Oy Method for the preparation of a library of derivatives of the SH3 domain of recombinant nephrocystin (NPHP1)
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
US10722589B2 (en) 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
SG10201912545PA (en) * 2017-04-24 2020-02-27 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019033051A1 (en) 2017-08-11 2019-02-14 City Of Hope RNA APTAMERS AGAINST THE TRANSFERRIN RECEPTOR (TFR)
WO2019033050A1 (en) * 2017-08-11 2019-02-14 City Of Hope BISPECIFIC MOLECULE FOR BINDING TO ANTIGEN
IL302613B2 (en) 2017-09-08 2025-04-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
WO2019051122A2 (en) * 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. CONDITIONAL ACTIVATED BOND FRACTIONS CONTAINING FC REGIONS
US20190153096A1 (en) 2017-10-02 2019-05-23 Covagen Ag Cd3/cd33 bispecific binding molecules
US20190100587A1 (en) 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
JP7475275B2 (ja) 2018-02-08 2024-04-26 ジェネンテック， インコーポレイテッド 二重特異性抗原結合分子及びその使用方法
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3164226A1 (en) 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
WO2021119505A1 (en) 2019-12-13 2021-06-17 Genentech, Inc. Anti-ly6g6d antibodies and methods of use
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20230100732A (ko) 2020-11-04 2023-07-05 제넨테크, 인크. 항-cd20/항-cd3 이중특이성 항체의 피하 투여
CA3196539A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
AU2021374594B2 (en) 2020-11-04 2026-03-05 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
US12291575B2 (en) 2021-05-14 2025-05-06 Genentech, Inc. Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
EP4405396A2 (en) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CA3247048A1 (en) 2022-04-13 2023-10-19 Genentech, Inc. PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025221728A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
MX2012002428A (es) * 2009-08-27 2012-09-12 Covagen Ag Compuestos de union il-17 y usos medicos de los mismos.
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
CN114805583A (zh) * 2010-05-27 2022-07-29 根马布股份公司 针对her2的单克隆抗体

Also Published As

Publication number Publication date
JP2016516789A (ja) 2016-06-09
CN105189544A (zh) 2015-12-23
ZA201507752B (en) 2017-03-29
EP2986630B1 (en) 2018-08-15
CA2908988A1 (en) 2014-10-23
EP2986630A1 (en) 2016-02-24
SG11201508231UA (en) 2015-11-27
PH12015502278A1 (en) 2016-02-01
BR112015026143A2 (pt) 2017-10-17
CL2015003085A1 (es) 2016-06-03
EA201592006A1 (ru) 2016-03-31
JP2019106997A (ja) 2019-07-04
HK1214605A1 (zh) 2016-07-29
WO2014170063A1 (en) 2014-10-23
MX2015014608A (es) 2016-03-03
AU2014256037B2 (en) 2017-09-21
KR20160002882A (ko) 2016-01-08
AU2014256037A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
JP6694808B2 (ja) 抗腫瘍活性を有する新規な二重特異的結合分子
JP7418346B2 (ja) ４－１ＢＢＬを含むＨｅｒ２標的化抗原結合分子
KR102505383B1 (ko) Dll3 표적 다중 특이성 항원 결합 분자 및 그의 사용
ES2910365T3 (es) Nuevos polipéptidos biespecíficos contra CD137
US20240383978A1 (en) Bispecific binding proteins that bind cd137 and a tumor associated antigen
JP6708635B2 (ja) ＣＤ３εおよびＲＯＲ１に対する二特異性抗体
JP2022514343A (ja) 腫瘍標的化アゴニストｃｄ２８抗原結合分子
RU2762704C2 (ru) Новое psma-связывающее антитело и его применения
JP2023513003A (ja) Ｃｄ２８シングルドメイン抗体ならびにその多価および多重特異性の構築物
AU2019356573A1 (en) PD-1 single domain antibodies and therapeutic compositions thereof
JP2022504822A (ja) Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
CN112218686A (zh) 具有受限cd3结合的多特异性多肽构建体以及相关方法和用途
CN120607624A (zh) 具有受限cd3结合的多特异性多肽构建体及其使用方法
TW201815820A (zh) 雙特異性t細胞活化抗原結合分子
JP2017520575A (ja) 二重特異的ヘテロ二量体ダイアボディおよびその使用
KR20180028548A (ko) Sirp-알파 도메인 또는 이의 변이체를 갖는 구조체
KR20180002782A (ko) 전립선 특이적 막 항원(psma) 이중특이성 결합제 및 그의 용도
WO2022242679A1 (en) Anti-cd137 antibodies and methods of use
CA3219672A1 (en) Anti-cea and anti-cd137 multispecific antibodies and methods of use
KR20230060527A (ko) Pd-1 폴리펩티드 변이체
TW202428608A (zh) 抗b7h3抗體以及其使用方法
CA3076630A1 (en) Transthyretin immunoglobulin fusions
US20240209113A1 (en) Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use
TW202430568A (zh) 抗b7h3抗體以及其使用方法
US20240317880A1 (en) Epithelial Cadherin-Specific Antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170224

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20170425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170425

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20170516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180517

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200420

R150 Certificate of patent or registration of utility model

Ref document number: 6694808

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees